title: Letter: safety and efficacy of sofosbuvir plus daclatasvir with ribavirin for 12 weeks in Chinese treatment-experienced cirrhotic genotype 1b patients with HCV.
authors.affiliation: Department of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
authors.forename: Q-L
authors.initials: QL
authors.lastname: Zeng
authors.affiliation: Department of Infectious Diseases, The Affiliated Hospital of Yan'an University, Yan'an, China.
authors.forename: C-X
authors.initials: CX
authors.lastname: Li
authors.affiliation: Research and Treatment Center of Infectious Diseases, Beijing 302 Hospital, Beijing, China.
authors.forename: D-W
authors.initials: DW
authors.lastname: Zhang
authors.affiliation: Department of Infectious Diseases, Henan Provincial People's Hospital, Zhengzhou, China.
authors.forename: W
authors.initials: W
authors.lastname: Li
authors.affiliation: Department of Infectious Diseases, The Affiliated Hospital of Yan'an University, Yan'an, China.
authors.forename: G-H
authors.initials: GH
authors.lastname: Xu
authors.affiliation: Department of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. johnyuem@zzu.edu.cn.
authors.forename: Z-J
authors.initials: ZJ
authors.lastname: Yu
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D005260:Female; D016174:Hepacivirus / Q000235:genetics*; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D008297:Male; D012254:Ribavirin / Q000627:therapeutic use*; D000069474:Sofosbuvir / Q000627:therapeutic use*
chemical_list: D000998:Antiviral Agents; D012254:Ribavirin; D000069474:Sofosbuvir